Switch theme
Sign up to access all valuation multiples
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
2018
55
Last FY Revenue n/a
LTM EBITDA -$115M
$44.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bicara Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$115M.
In the most recent fiscal year, Bicara Therapeutics achieved revenue of n/a and an EBITDA of -$82.3M.
Bicara Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bicara Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$115M | XXX | -$82.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$110M | XXX | -$82.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$95.3M | XXX | -$68.0M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bicara Therapeutics's stock price is $9.
Bicara Therapeutics has current market cap of $506M, and EV of $44.1M.
See Bicara Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44.1M | $506M | XXX | XXX | XXX | XXX | $-3.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bicara Therapeutics has market cap of $506M and EV of $44.1M.
Bicara Therapeutics's trades at n/a EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Bicara Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bicara Therapeutics has a P/E ratio of -5.3x.
See valuation multiples for Bicara Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $506M | XXX | $506M | XXX | XXX | XXX |
| EV (current) | $44.1M | XXX | $44.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.3x | XXX | -7.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBicara Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
Bicara Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bicara Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bicara Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 52% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bicara Therapeutics acquired XXX companies to date.
Last acquisition by Bicara Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Bicara Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bicara Therapeutics founded? | Bicara Therapeutics was founded in 2018. |
| Where is Bicara Therapeutics headquartered? | Bicara Therapeutics is headquartered in United States of America. |
| How many employees does Bicara Therapeutics have? | As of today, Bicara Therapeutics has 55 employees. |
| Who is the CEO of Bicara Therapeutics? | Bicara Therapeutics's CEO is Dr. Claire Mazumdar, M.B.A.,P.H.R.,PhD. |
| Is Bicara Therapeutics publicy listed? | Yes, Bicara Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Bicara Therapeutics? | Bicara Therapeutics trades under BCAX ticker. |
| When did Bicara Therapeutics go public? | Bicara Therapeutics went public in 2024. |
| Who are competitors of Bicara Therapeutics? | Similar companies to Bicara Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bicara Therapeutics? | Bicara Therapeutics's current market cap is $506M |
| Is Bicara Therapeutics profitable? | Yes, Bicara Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bicara Therapeutics? | Bicara Therapeutics's last 12 months EBITDA is -$115M. |
| What is the current EV/EBITDA multiple of Bicara Therapeutics? | Current EBITDA multiple of Bicara Therapeutics is -0.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
